An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Crossover Truncated Four Period Fully Replicate Reference Scaled Average Oral Bioequivalence Study Comparing Relugolix 120 mg Tablets Manufactured By BDR Pharmaceuticals Internationals Pvt Ltd India With Orgovyx (Relugolix) 120 MG Tablets Distributed By Sumitomo Pharma America Inc In Healthy Adult Human Male Subjects Under Fed Conditions - NIL

Start Date01 Jul 2025

Sponsor / Collaborator

BDR Pharmaceuticals International Pvt Ltd.

NCT06837896

/ Not yet recruitingPhase 3

A Multicenter Study Evaluating the Efficacy and Safety of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.

Start Date01 Feb 2025

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

NCT06650579

/ RecruitingPhase 3IIT

Randomized Controlled Trial of Leuprolide Plus Abiraterone Acetate (AA) Versus Relugolix Plus AA for Advanced Prostate Cancer: the REVELUTION-2 Trial

This phase III/IV trial compares the impact of leuprolide and abiraterone acetate (AA) versus relugolix and AA on the heart in hormone-naive patients with advanced prostate cancer receiving pelvic radiation therapy. Leuprolide is in a class of medications called gonadotropin-releasing hormone agonists (GNRHa). It prevents the body from making luteinizing hormone-releasing hormone (LHRH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone (a male hormone) in men and may stop the growth of prostate tumor cells that need testosterone to grow. Abiraterone acetate, an androgen biosynthesis inhibitor, works by decreasing the amount of certain hormones in the body. Relugolix, a GNRH antagonist, works by decreasing the amount of testosterone produced by the body. This may slow or stop the spread of prostate tumor cells that need testosterone to grow. The use of hormone therapy with radiation therapy has been shown to improve survival, however, studies have suggested that the addition of hormone therapy may worsen heart (cardiac) disease and high blood pressure. In fact, studies have shown that the most common cause of death in prostate cancer patients is due to heart disease or heart attacks. Computed tomography (CT) scans create a series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine. In this study, sophisticated cardiac CT images are used to take pictures of patients' heart and coronary arteries to help assess damage to the heart. Using cardiac CT and blood tests, this trial may help doctors determine which patients are at risk of cardiac disease when treated with combination hormone therapy, as well as the differential risk of leuprolide versus relugolix in combination with abiraterone acetate.

Start Date31 Jan 2025

Sponsor / Collaborator

Emory University

[+4]

100 Clinical Results associated with Relugolix

100 Translational Medicine associated with Relugolix

100 Patents (Medical) associated with Relugolix

198

Literatures (Medical) associated with Relugolix

01 Feb 2025·Pharmacology Research & Perspectives

Transfer of the Oral Gonadotropin‐Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women

Article

Author: Lee, Sarah ; Brimhall, Darin B. ; Yoshida, Kazumasa ; Chen, Yu‐Luan ; Ufer, Mike

ABSTRACT:

Relugolix is an oral gonadotropin‐releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed‐dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h. Pharmacokinetic parameters were determined, including the cumulative amount of relugolix excreted into breast milk to derive the total infant dose. The safety and tolerability of relugolix were also assessed. Eight healthy lactating women were enrolled and completed the study per protocol. Relugolix was safe and well tolerated based on adverse events and other safety data. It was excreted into breast milk with a median time to peak concentration (tmax) of 5.81 h and a geometric mean peak concentration (Cmax) of 15.7 ng/mL, similar to corresponding plasma data from previous clinical studies. The mean cumulative amount of relugolix excreted was 0.0051 mg over 24 h and 0.0067 mg over 120 h, corresponding to 0.0128% and 0.0167% of the maternal dose, respectively. The body weight‐adjusted relative daily infant dose of approximately 0.25% suggests a 400‐fold lower newborn than maternal relugolix exposure. Relevant effects of relugolix on the breastfed child appear unlikely given its limited excretion into breast milk of lactating women but cannot be fully excluded in the absence of infant safety data.

02 Jan 2025·Future Oncology

Plain language review: the safety of relugolix combination therapy for advanced prostate cancer

Article

Author: Gatoulis, Sergio C. ; Flanders, Scott C. ; La Cerda, Jose De ; Shore, Neal D. ; Thorley, Jared ; Cookson, Michael S. ; Sieber, Paul

WHAT IS THIS SUMMARY ABOUT?:

Advanced prostate cancer is a cancer that began in the prostate (a part of the male body) and has spread to other parts of the body. This is a review of two clinical research studies of patients with advanced prostate cancer who were treated with relugolix combination therapy. Relugolix is a medicine taken by mouth that lowers a male sex hormone, called testosterone. Relugolix is sometimes combined with other medicines such as novel hormonal therapies (NHTs) or chemotherapy to treat advanced prostate cancer. In one study, patients were treated with relugolix combined with an NHT (abiraterone or apalutamide). In a second study, patients were treated with relugolix combined with an NHT (enzalutamide) or chemotherapy (docetaxel). Researchers wanted to understand what possible side effects may happen due to taking these medicines together as prescribed. They also wanted to see if relugolix combination therapy worked to lower testosterone in the same way as relugolix taken alone.

WHAT ARE THE KEY TAKEAWAYS?:

Researchers found that most of the side effects of relugolix combined with an NHT or chemotherapy were mild or moderate. Side effects of relugolix combination therapy were similar to the side effects of the medicines when taken alone. However, patients who received relugolix with enzalutamide or docetaxel were more likely to have a serious side effect compared with patients who received relugolix taken alone. Testosterone stayed below 50 nanograms per deciliter (known as castration levels) for patients who received relugolix with NHT or chemotherapy.

WHAT WERE THE MAIN CONCLUSIONS REPORTED BY THE RESEARCHERS?:

Patients who receive relugolix combination therapy generally experience mild or moderate side effects, rather than serious side effects. No new safety issues were found during these studies. Patients maintained low testosterone levels. Patients and their doctors should discuss the benefits and possible harms of relugolix combination therapy to treat advanced prostate cancer.

01 Jan 2025·EUROPEAN UROLOGY

Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Article

Author: Tombal, Bertrand ; Shore, Neal ; Bossi, Alberto ; Brown, Bruce ; Collins, Sean ; Hunsche, Elke ; Morgans, Alicia K. ; Zhu, Emily

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated testosterone suppression to castrate levels in men with advanced prostate cancer (PCa) in the HERO study.Since advanced PCa and its treatments can impact patients' daily life, it is imperative to understand the impact of systemic therapy on patient health-related quality of life (HRQOL).To report the HRQOL for patients on relugolix compared with those on leuprolide in on-treatment and testosterone recovery periods of the HERO study.A phase 3 randomized controlled study was conducted in 934 patients with advanced PCa.Patients underwent 2:1 randomization and received relugolix 120 mg orally once daily or leuprolide 3-mo injections for 48 wk.Testosterone recovery was evaluated in a patient subset.HRQOL evaluations were based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) and the Prostate Cancer Module (EORTC QLQ-PR25) during treatment and testosterone recovery phases.In a post hoc anal., predictors of HRQOL deterioration were evaluated.No statistically significant differences between the two groups were found in changes from baseline to the end of treatment in either the EORTC QLQ-C30 or the EORTC QLQ-PR25 instrument.During the testosterone recovery phase, hormonal treatment-related symptoms scores were lower for relugolix than for leuprolide, suggesting a lower burden of hormone-related symptoms associated with a treatment that has more rapid testosterone recovery after treatment cessation.Limitations include low patient numbers in the testosterone recovery group.Oral relugolix is a therapeutic option with similar patient-reported HRQOL to leuprolide, providing an oral option for androgen deprivation therapy associated with a more rapid testosterone reductionIn men with advanced prostate cancer, relugolix had similar health-related quality of life to leuprolide.

News (Medical) associated with Relugolix

29 Jan 2025

·www.prnewswire.com

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global expertise in product commercialization. She has been instrumental in the development and approval of multiple drugs across several therapeutic areas, including blockbuster medicines like LIPITOR® and CRESTOR®," said Todd Harris, CEO of TYRA. "Adele has a diversified background both as a pharmaceutical executive and board member, with a wealth of knowledge in growing oncology business units. Her experience in launching ORGOVYX® for prostate cancer will be particularly valuable as we plan for late-stage development of TYRA-300 in non-muscle invasive bladder cancer. We look forward to Adele's insights as we advance our precision medicine pipeline and continue to grow TYRA." Most recently, Ms. Gulfo served as Chief Executive Officer, Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. where she led the commercial and development portfolio for multiple therapeutic areas including oncology, rare disease, urology, CNS and Women's Health. Previously, Ms. Gulfo served as chief commercial and business development officer at Sumitovant Biopharma from 2020 to 2023. Previously, she served as chief commercial development officer at Roivant Sciences, where she was influential in the formation of Sumitovant and in preparations for the launches of key brands, including ORGOVYX® (prostate cancer), GEMTESA (overactive bladder), RETHYMIC (congenital athymia), and MYFEMBREE (women's health). Adele was the president and general manager of Pfizer's $12B+ U.S. primary care business unit, as well as country manager for Pfizer's U.S. Biopharma business, including specialty and oncology business units. Earlier in her career at Pfizer, Adele was instrumental in the development, launch, and commercial success of LIPITOR®, which became the world's best-selling medicine. Prior to Pfizer, Adele held vice president roles within AstraZeneca, including business development and innovation and commercial readiness, as well as the multi-billion-dollar cardiovascular business unit. She oversaw the launch of Crestor® and its growth into a $2 billion medicine. Ms. Gulfo received a BS in biology from Seton Hall University and an MBA in marketing with highest honors from Fairleigh Dickinson University. She studied post-graduate molecular biology at the University of Medicine and Dentistry of New Jersey where she began her career. Ms. Gulfo has been awarded several patents over her career and has extensive public company board experience. Currently, Ms. Gulfo serves on the board of directors of Enpro, a publicly traded industrial engineering firm, and the Innovation Growth Board for Mass General Brigham, the largest hospital-based research enterprise in the United States. "TYRA has great potential to develop best-in-class precision medicines in therapeutic areas like non-muscle invasive bladder cancer and skeletal dysplasia, which represent large market opportunities where innovation is desperately needed," said Ms. Gulfo. "I look forward to partnering with the executive leadership team and other members of the board and leveraging my experience to advance and grow TYRA's pipeline." About Tyra Biosciences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA. For more information about our science, pipeline and people, please visit and engage with us on LinkedIn. Forward-Looking Statements TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the expected advancement of our pipeline and our growth; the potential to develop next-generation precision medicines and their potential to be first-in-class and/or best-in-class; the potential safety and therapeutic benefits of, and market opportunities for, our product candidates; the expected timing and phase of development of TYRA-300; and the potential for SNÅP to develop therapies. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: later developments with the FDA may be inconsistent with prior feedback from the FDA; we are early in our development efforts, have only recently begun testing TYRA-300 and TYRA-200 for oncology in clinical trials and the approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies and clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Amy Conrad [email protected] SOURCE Tyra Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangePhase 2

05 Sep 2024

·pmlive.com

MHRA authorises first in new class of treatment for endometriosis symptoms

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence for Gedeon Richter’s Ryeqo for adults with endometriosis symptoms, making it the first in a new class of treatments authorised in the UK for this patient population. Those eligible to receive the combination therapy, which consists of non-peptide gonadotrophin-releasing hormone receptor antagonist relugolix 40mg, estradiol 1mg and norethisterone acetate 0.5mg taken in a single once-daily tablet, will be of reproductive age and have a history of previous medical or surgical treatment for their endometriosis. Affecting approximately 176 million women worldwide, endometriosis is a chronic condition that occurs when tissue similar to the lining of the uterus grows outside of the uterus. Patients can experience a range of symptoms, including dysmenorrhoea (painful cramping, usually in the lower abdomen), heavy bleeding and pelvic pain, and the disease can be associated with sub-fertility or infertility. The MHRA’s decision was supported by positive results from the late-stage SPIRIT programme, in which significantly more patients achieved pain reduction with Ryeqo versus placebo at 24 weeks. In the SPIRIT 1 study, 75% of patients responded to Ryeqo for their dysmenorrhoea compared to 27% in the placebo arm. The same result was seen in the SPIRIT 2 trial, with 75% of dysmenorrhoea responders in the Ryeqo cohort compared to 30% for placebo. Additionally, 59% and 66% of patients responded to Ryeqo for their non-menstrual pelvic pain (NMPP) in SPIRIT 1 and 2, respectively, compared to 40% and 43% of those receiving placebo. Dysmenorrhoea and NMPP reduction was also sustained over two years with Ryeqo treatment, according to results from a long-term extension study. David Jordan, medical director UK and Ireland, Gedeon Richter, said: “The MHRA’s decision to licence relugolix combination therapy in endometriosis is fantastic news and we are delighted the need for more treatment options has been recognised. “We have been working hard to bring a new way of treating the condition to clinicians and women suffering with painful symptoms and we believe this authorisation will be a welcome step for redefining care.” Jordan added that the company is now engaging with the relevant health authorities throughout the UK “with a view to securing NHS reimbursement as soon as possible.”

Clinical ResultDrug Approval

14 Aug 2024

·firstwordpharma.com

NICE greenlights first oral prostate cancer ADT

The UK's National Institute for Health and Care Excellence (NICE) issued final guidance Wednesday recommending Orgovyx (relugolix) as an oral androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer in England. The decision, following draft guidance released last month, offers eligible patients an alternative to injectable ADTs for the first time.The oral GnRH antagonist is marketed by Accord Healthcare in Europe under an agreement with Sumitomo Pharma. Pfizer co-markets the drug with Sumitomo in the US.NICE's recommendation states that Orgovyx is approved as an option for treating prostate cancer in adults with advanced hormone-sensitive disease, alongside radiotherapy for high-risk, localised or locally advanced disease, and as a neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced disease.The drug was approved in Europe in 2022 based on the Phase III HERO trial, which compared daily oral Orgovyx to leuprolide, a synthetic ADT given by depot subcutaneous or intramuscular injection every three months. Results demonstrated that 96.7% of men receiving Orgovyx maintained castration from day 29 through 48 weeks, compared to 88.8% for leuprolide. The study also showed a lower incidence of major adverse cardiovascular events in the Orgovyx arm (2.9%) versus the leuprolide group (6.2%).Paul Tredwell, executive vice president at Accord for the EMENA region, stated, "The publication of NICE's final guidance is a hugely positive step for patients living with prostate cancer in England… We are pleased to provide an additional treatment choice to the clinical community and those eligible men living with prostate cancer."

Phase 3Clinical ResultDrug Approval

100 Deals associated with Relugolix

External Link

KEGG	Wiki	ATC	Drug Bank
D10888	Relugolix	L01XX	DB11853

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced Prostate Carcinoma	CA	Sumitomo Pharma Co., Ltd.	10 Oct 2023
Castration-sensitive prostate cancer	EU	Accord Healthcare SLU	29 Apr 2022
Castration-sensitive prostate cancer	IS	Accord Healthcare SLU	29 Apr 2022
Castration-sensitive prostate cancer	LI	Accord Healthcare SLU	29 Apr 2022
Castration-sensitive prostate cancer	NO	Accord Healthcare SLU	29 Apr 2022
Endometriosis	JP	ASKA Pharmaceutical Co., Ltd.	24 Dec 2021
Prostatic Cancer	US	Sumitomo Pharma Co., Ltd.	18 Dec 2020
Leiomyoma	JP	ASKA Pharmaceutical Co., Ltd.	08 Jan 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Prostate Carcinoma	Phase 3	US	Sumitomo Pharma America, Inc.	31 Jan 2025
Recurrent Prostate Carcinoma	Phase 3	US	Pfizer Inc.	31 Jan 2025
Menorrhagia	Phase 3	US	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	BR	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	IT	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	PL	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	ZA	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	GB	Myovant Sciences GmbH	26 Apr 2017
Uterine Fibroids	Phase 3	US	Myovant Sciences GmbH	26 Apr 2017
Uterine Fibroids	Phase 3	BR	Myovant Sciences GmbH	26 Apr 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04666129 (ASCO_GU2025) Manual	Phase 1	Advanced Prostate Carcinoma	24	Relugolix 120 mg + Abiraterone 1000 mg + prednisone 5 mg/methylprednisolone 4 mg (Part 1)	yknoiksqly(ziedzlzdos) = kcacpaoeoz niqcexanuu (sbgphilclz, 3.2) View more	Positive	13 Feb 2025
				Relugolix 240 mg + Apalutamide 240 mg	yknoiksqly(ziedzlzdos) = mjdcoaxjbe niqcexanuu (sbgphilclz, 8.0) View more
ASCO_GU2025	Not Applicable	-	5,274	relugolix (Nonmetastatic Prostate Cancer (nmPC))	erfcywydkg(jbxbjkgvkc) = llqnhuqczm rrogdxrgwn (udgwcmbozb, ±10 [99]) View more	-	13 Feb 2025
				relugolix (Metastatic Prostate Cancer (mPC))	erfcywydkg(jbxbjkgvkc) = psehezfrgk rrogdxrgwn (udgwcmbozb, ±10 [99]) View more
NCT03751124 (CTgov)	Phase 3	Menorrhagia \| Uterine Fibroids	229	Relugolix+E2/NETA (Relugolix Plus E2/NETA (Group A))	wywawzmkks(enwjpwyimo) = pvkgxduroz xmrvablmet (prmplungpg, ivbnocgkpt - lvyeqwyrwj) View more	-	25 Jun 2024
				Placebo (Placebo (Group B))	wywawzmkks(enwjpwyimo) = zzfpegnevf xmrvablmet (prmplungpg, hbcrfhiulh - nqosdklmbf) View more
NCT05467176 (OPTYX study, ASCO2024)	Not Applicable	Usher Syndromes PSA \| testosterone \| distant metastases	394	Relugolix monotherapy	bxdxhzglrs(ktmammnaon) = qzgbgduzcm zctachzfzn (hycyfpztvb, 238.5) View more	-	24 May 2024
ASCO2024	Not Applicable	-	267	Relugolix	xqrgirwcke(flthfogwpa) = acute heart failure decompensation, sick sinus syndrome, ventricular tachycardia, and death during treatment bdbdliskuy (damircdkvp )	-	24 May 2024
NCT03412890 (CTgov)	Phase 3	Menorrhagia \| Uterine Fibroids	477	Relugolix+E2/NETA (Relugolix Plus E2/NETA (Group A))	ltcftyzsjk(dgegplyben) = uxxucxlrhv woqjrxgcxk (akdqxlonoc, mxviumvxjz - nwjfhiyefv) View more	-	09 May 2024
				Relugolix+E2/NETA (Relugolix Plus Delayed E2/NETA (Group B))	ltcftyzsjk(dgegplyben) = tqwaneeqcd woqjrxgcxk (akdqxlonoc, rjihbsmpww - jieupbuaar) View more
AUA2024	Not Applicable	Advanced Prostate Carcinoma	-	Leuprolide	iavoksvsno(rabedrkxyd) = lajitxbzkh wkjgfaxlkf (jxcepaubyc )	-	01 May 2024
				Relugolix	iavoksvsno(rabedrkxyd) = cmhvndcrmm wkjgfaxlkf (jxcepaubyc )
NCT03103087 \| NCT03049735 \| NCT03412890 (Pubmed \| Am J Obstet Gynecol)	Phase 3	Uterine Fibroids	-	Relugolix combination therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg)	wtgjzuwbfi(phvnmsnhek) = 5.7% ptbrwzjzev (buhxxwzhdx ) View more	-	01 Feb 2024
NCT03085095 (HERO, ASCO_GU2024) Manual	Phase 3	Prostatic Cancer	25	Relugolix	zealhyjqxu(rbvcocjgpa) = mxvimqxqxy koijegcyka (xdzntbytxg, 0.67 - 2.5) View more	Positive	25 Jan 2024
HERO study (ASCO_GU2024)	Not Applicable	Advanced Prostate Carcinoma	152	Relugolix	ezoazkkuet(fvupsypmta) = Three pts (2%) had a major adverse cardiovascular event, including one sudden death, one with congestive heart failure, and one with myocardial infarction. Two pts (1%) reported grade 3 fatigue. G3 LFT elevations recorded in 2 pts (1%). No clinical signals of DDI reported. otonhwqmou (qilsdfsfja )	Positive	25 Jan 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis